Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.51 (¥3,470)+0.93%▲ (in JPY terms)
SoftBank|$33.62 (¥5,424)-9.01%▼ (in JPY terms)
MUFG|$21.53 (¥3,473)-4.30%▼ (in JPY terms)
Keyence|$439.33 (¥70,880)-4.28%▼ (in JPY terms)
Nintendo|$45.21 (¥7,294)+3.02%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.13%▲ (in JPY terms)
Takeda|$33.97 (¥5,480)+2.53%▲ (in JPY terms)
Tokyo Electron|$403.50 (¥65,100)-8.17%▼ (in JPY terms)
Recruit|$79.46 (¥12,820)+1.63%▲ (in JPY terms)
ITOCHU|$11.79 (¥1,903)-0.89%▼ (in JPY terms)
Honda|$9.52 (¥1,536)-1.48%▼ (in JPY terms)
Shin-Etsu|$44.36 (¥7,157)-2.77%▼ (in JPY terms)
Tokio Marine|$46.65 (¥7,526)-0.97%▼ (in JPY terms)
Fast Retailing|$488.67 (¥78,840)+0.00%▲ (in JPY terms)
Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.51 (¥3,470)+0.93%▲ (in JPY terms)
SoftBank|$33.62 (¥5,424)-9.01%▼ (in JPY terms)
MUFG|$21.53 (¥3,473)-4.30%▼ (in JPY terms)
Keyence|$439.33 (¥70,880)-4.28%▼ (in JPY terms)
Nintendo|$45.21 (¥7,294)+3.02%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.13%▲ (in JPY terms)
Takeda|$33.97 (¥5,480)+2.53%▲ (in JPY terms)
Tokyo Electron|$403.50 (¥65,100)-8.17%▼ (in JPY terms)
Recruit|$79.46 (¥12,820)+1.63%▲ (in JPY terms)
ITOCHU|$11.79 (¥1,903)-0.89%▼ (in JPY terms)
Honda|$9.52 (¥1,536)-1.48%▼ (in JPY terms)
Shin-Etsu|$44.36 (¥7,157)-2.77%▼ (in JPY terms)
Tokio Marine|$46.65 (¥7,526)-0.97%▼ (in JPY terms)
Fast Retailing|$488.67 (¥78,840)+0.00%▲ (in JPY terms)

DAIICHI SANKYO COMPANY,LIMITED

2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of datopotamab deruxtecan (Dato-DXd/DS-1062) as a first-line treatment for triple-negative breast cancer (248.5KB) will open in a new window as a PDF file.”

by

2026-06-29 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approv … 続きを読む

2026-05-25 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (311.8KB) regarding the partial amendment approval of Datroway® (datopotamab deruxtecan) for the first-line treatment of triple-negative breast cancer in the United States will open in a new window.”

by

2026-05-25 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (311.8KB) regarding the partial amendment approv … 続きを読む

2026-05-18 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (277.7KB) regarding the approval of two partial changes to the Enhertu® (trastuzumab deruxtecan) drug for HER2-positive early-stage breast cancer in the United States will open in a new window.”

by

2026-05-18 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (277.7KB) regarding the approval of two partial … 続きを読む

2026-05-11 DAIICHI SANKYO COMPANY,LIMITED “Notice of manufacturing and marketing approval in Japan for the dried attenuated live measles, mumps, and rubella combined vaccine "Mimlit® for subcutaneous injection" (176.8KB). (PDF file will open in a new window.)”

by

2026-05-11 DAIICHI SANKYO COMPANY,LIMITED “Notice of manufacturing and marketing approval in Japan for t … 続きを読む

Contact